ALA. G. Loseva

A. G. Loseva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. G. Loseva has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Extracorporeal membrane oxygenation in acute respiratory failure in oncohematological patients

    by G. M. Galstyan, A. E. Shchekina, M. V. Spirin, S. A. Nalbandyan, I. A. Zemlyakov, A. G. Loseva, A. Yu. Mashkov, A. M. Kovrigina, Г. М. Галстян, А. Е. Щекина, et al.

    Introduction. Pulmonary complications and acute respiratory failure (ARF) are among the most severe complications of hematologic malignancies and their treatment. When conventional respiratory support fails, extracorporeal membrane oxygenation (ECMO) may serve as a rescue therapy. However, its use in patients with hematologic malignancies remains controversial. The objective was to present a case series of veno-venous ECMO support for ARF in patients with hematologic malignancies and to evaluate the outcomes. Materials and methods. A retrospective study was conducted at the National Medical Research Center for Hematology and included adult patients with diseases of the hematopoietic system who required ECMO support for severe acute respiratory failure between 2018 and 2025. The clinical characteristics of patients, the stage and type of tumor disease, prior treatment, indices of organ dysfunction (APACHE II, SOFA), parameters of gas-exchange and hemostasis were evaluated. The etiology of pulmonary involvement was investigated, and central hemodynamic parameters, coagulation profiles and laboratory findings were monitored. Duration of ECMO support, the need for renal replacement therapy, treatment-related complications, and clinical outcomes were recorded. Descriptive statistical methods were applied; results are presented as medians with interquartile ranges. Overall survival was estimated using the Kaplan – Meier method. Results. The study cohort comprised 8 adult patients with different hematologic malignancies. Prior to ECMO initiation, all patients exhibited severe hypoxemia unresponsive to conventional respiratory support. Infectious lung injury of mixed etiology was identified in most cases, whereas neoplastic pulmonary infiltration was diagnosed in one patient. Thrombocytopenia (< 50×10⁹/L) was present in 63% of patients. The median duration of ECMO therapy was 13 days. Successful discontinuation of ECMO support was achieved in two patients. Major complications were predominantly hemorrhagic, including intracranial bleeding, and were frequently associated with significant coagulation disturbances complicating anticoagulation management. Conclusion. VV-ECMO may serve as a rescue therapy for selected patients with hematologic malignancies who develop refractory acute respiratory failure. However, its use is associated with a substantial risk of severe complications and poor outcomes. Careful patient selection is therefore essential and should consider the prognosis of the underlying disease, the likelihood of bone marrow recovery, and the potential effectiveness of antitumor therapy. Early identification of the cause of pulmonary injury and timely initiation of appropriate targeted treatment are critical factors influencing the success of ECMO support.

  • Open Access

    Immunophenotyping of blood and bone marrow cells as a way to search for differentiation syndrome risk factors in acute promyelocytic leukemia

    by A. A. Semenova, I. V. Galtseva, V. V. Troitskaya, N. M. Kapranov, Yu. O. Davydova, K. A. Nikiforova, A. G. Loseva, A. A. Ermolaev, V. A. Surimova, S. M. Kulikov, et al.

    Background. Differentiation syndrome (DS) is a potentially fatal complication of therapy for acute promyelocytic leukemia (APL) with an incidence of up to 48 %. To date, no reliable DS risk factors have been found, with the exception of leukocytosis at the APL onset.Aim. To determine the risk factors associated with DS in patients with APL during induction therapy with arsenic trioxide (ATO) and tretinoin (ATRA).Materials and methods. The study included 39 patients with APL, 29 (74.4 %) of them were classified as low-risk according to ELN (European Leukemia Net), 10 (25.6 %) were classified as high-risk. At the disease onset, cytological and molecular (chimeric transcript PML::RARα, FLT3-ITD mutation) bone marrow studies were performed, the expression of 28 differentiation antigens by blood and bone marrow blast cells was determined (markers of early precursors, myeloid and lymphoid differentiation, cell adhesion molecules, chemokine receptors, integrins, selectin), body mass index (BMI) and the leukocytes number dynamics during induction course were assessed. All patients received ATRA and ATO therapy. Patients from the high-risk group at the onset received 1–3 injections of idarubicin (12 mg/m2) and dexamethasone (8–10 mg/m2 2 times a day) to prevent DS until leukocytosis reduced. In cases of DS, dexamethasone was prescribed at a dose of 10 mg/m2 2 times a day; in cases of severe DS, the induction course was interrupted.Results. Of the 39 patients, 12 (30.8 %) were diagnosed with DS: 20 % of high-risk patients (2/10) and 34.5 % of low-risk patients (10/29). There was no statistically significant association of leukocytosis more than 10 × 109 /L at onset, microgranular morphology of blast cells, bcr3-variant PML::RARα, FLT3-ITD mutation with DS. In multivariate analysis, the probability of DS was associated with BMI ≥30 kg/m2 and mean fluorescence intensity of CD38 antigen by blast cells, regardless of risk group. based on the results of the ROC-analysis, the threshold value of mean CD38 fluorescence intensity was set at 25,000 cu, if exceeded, DS is highly likely to develop.Conclusion. the high incidence of DS among low-risk patients is probably due to the lack of prophylactic glucocorticosteroids administration for the development of leukocytosis during ATRA and ATO therapy. BMI ≥30 kg/m2 and mean CD38 fluorescence intensity more than 25,000 cu were identified as statistically significant DS risk factors.